Abu Sufiyan Chhipa
Nirma University of Science and Technology
18 Papers
7 Citations
Abu Sufiyan Chhipa is an academic researcher from Nirma University of Science and Technology. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 5, co-authored 12 publications.
Chat about Author
Papers
Molecular and cellular paradigms of multidrug resistance in cancer.
Foram U. Vaidya,Abu Sufiyan Chhipa,Vinita Mishra,Vishal Gupta,Shiv Govind Rawat,Ajay Kumar,Chandramani Pathak +6 more
- 13 Oct 2020
TL;DR: An improved understanding of the molecular mechanism of multi drug resistance and cellular reprogramming can provide a promising opportunity to combat drug resistance in cancer and intensify anti-cancer therapy for the upcoming future.
144
AGE-RAGE synergy influences programmed cell death signaling to promote cancer
Bhargav N. Waghela,Foram U. Vaidya,Kishu Ranjan,Abu Sufiyan Chhipa,Budhi Sagar Tiwari,Chandramani Pathak +5 more
TL;DR: Multiple molecular paradigms relevant to cell death particularly Apoptosis, Autophagy, and Necroptosis that are considerably influenced by the AGE-RAGE signaling in the cancer cells are focused on.
93
Management of Type 2 Diabetes: Current Strategies, Unfocussed Aspects, Challenges, and Alternatives
TL;DR: The employability of phytoconstituents as multitargeting molecules and their potential use as effective therapeutic adjuvants to first line hypoglycemic agents to prevent side effects caused by the synthetic drugs are discussed.
PCOS and Depression: Common Links and Potential Targets.
TL;DR: In this paper, the authors have attempted to shed light on common associations/shared links between depression and polycystic ovary syndrome with respect to the levels of cortisol, androgen, vitamin D, neurotransmitters, monoaminoxidase (MAO), and insulin-like growth factor-1 (IGF-1).
62
Targeting receptors of advanced glycation end products (RAGE): Preventing diabetes induced cancer and diabetic complications.
TL;DR: Inhibition of RAGE signaling can prevent diabetic complications and cancer in diabetic patients and can be helpful in the management of worsening diabetic complications in diabetic cancer patients.
32